Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 7, 2006, Pages 10-17

  Brunette, Mary F ^a,b   Mueser, Kim T ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADDICTION; BEHAVIOR THERAPY; BIPOLAR DISORDER; COGNITIVE THERAPY; COMORBIDITY; DISEASE ASSOCIATION; FINANCIAL MANAGEMENT; HUMAN; LONG TERM CARE; MENTAL DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SUBSTANCE ABUSE; TREATMENT PLANNING;

COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; LONG-TERM CARE; MENTAL DISORDERS; PATIENT CARE PLANNING; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS;

EID: 33748634614     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Kendler KS, Gallagher TJ, Abelson JM, et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry 1996;53:1022-1031
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518
3. Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002;59:375-380
4. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273-279
5. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of the recent literature. J Clin Psychiatry 2002;63:892-909
6. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-858
7. Swartz MS, Swanson JW, Hiday VA, et al. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 1998;155:226-231
8. Goodman LA, Rosenberg SD, Mueser KT, et al. Physical and sexual assault history in women with serious mental illness: prevalence, correlates, treatment, and future research directions. Schizophr Bull 1997;23:685-696
9. Hurlburt MS, Hough RL, Wood PA. Effects of substance abuse on housing stability of homeless mentally ill persons in supported housing. Psychiatr Serv 1996;47:731-736
10. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861
11. Abram KM, Teplin LA. Co-occurring disorders among mentally ill jail detainees: implications for public policy. Am Psychol 1991;46:1036-1045
12. Compton MT, Weiss PS, West JC, et al. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol 2005;40:939-946
13. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001;91:31-37
14. Judd PH, Thomas N, Schwartz T, et al. A dual diagnosis demonstration project: treatment outcomes and cost analysis. J Psychoactive Drugs 2003;35(suppl 1):181-192
15. Dixon L, McNary S, Lehman A. Substance abuse and family relationships of persons with severe mental illness. Am J Psychiatry 1995;152:456-158
16. Drake RE, Mueser KT, Brunette MF, et al. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J 2004;27:360-374
17. Drake RE, McHugo GJ, Clark RE, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998;68:201-215
18. Mueser KT, Noordsy DL, Drake RE, et al. Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, NY: Guilford Press; 2003
19. Osher FC, Drake RE, Noordsy DL, et al. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J Clin Psychiatry 1994;55:109-113
20. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999;35(suppl):93-100
21. Essock SM, Mueser KT, Drake RE, et al. Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv 2006;57:185-196
22. Brunette MF, Mueser KT, Drake RE. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev 2004;23:471-481
23. Ries RK, Comtois KA. Managing disability benefits as part of treatment for persons with severe mental illness and comorbid drug/alcohol disorders: a comparative study of payee and non-payee participants. J Addict 1997;6:330-338
24. Ries RK, Dyck DG, Short R, et al. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv 2004;55:445-447
25. Mueser KT, Fox L, Mercer C. Family intervention for severe mental illness and substance use disorder. In: Schaub A, ed. New Family Interventions and Associated Research in Psychiatric Disorders. Vienna, Austria: Springer-Verlag; 2002:205-227
26. Harris M. Trauma Recovery and Empowerment: A Clinician's Guide for Working With Women in Groups. New York, NY: The Free Press; 1998
27. Rosenberg SD, Mueser KT, Friedman MJ, et al. Developing effective treatments for posttraumatic disorders among people with severe mental illness. Psychiatr Serv 2001;52:1453-1461
28. O'Keefe C, Potenza DP, Mueser KT. Treatment outcomes for severely mentally ill patients on conditional discharge to community-based treatment. J Nerv Ment Dis 1997;185:409-411
29. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Prog Behav Modif 1992;28:183-218
30. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry 1989;40:1025-1030
31. McHugo GJ, Drake RE, Burton HL. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 1995;183:762-767
32. Drake RE, Mercer-McFadden C, Mueser KT. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998;24:589-608
33. Mangrum LF, Spence RT, Lopez M, et al. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat 2006;30:79-84
34. Ho AP, Tsuang JW, Liberman RP, et al. Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry 1999;156:1765-1770
35. Mueser KT, Fox L. A family intervention program for dual disorders. Community Ment Health J 2002;38:253-270
36. Miller WR, Rollnick S, eds. Motivational Interviewing: Preparing People for Change. 2nd ed. New York, NY: Guilford Press; 2002
37. Helmus TC, Saules KK, Schoener EP, et al. Reinforcement of counseling attendance and alcohol abstinence in a community-based dual diagnosis treatment program: a feasibility study. Psychol Addict Behav 2003;17:249-251
38. Petry NM, Martin B, Simcic F Jr. Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic. J Consult Clin Psychol 2005;73:354-359
39. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. J Nerv Ment Dis 1999;187:630-635
40. Carey KB, Purnine DM, Maisto SA, et al. Enhancing readiness-to-change substance abuse in persons with schizophrenia: a four-session motivation-based intervention. Behav Modif 2001;25:331-384
41. Graeber DA, Moyers TB, Griffith G, et al. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003;39:189-202
42. James W, Preston NJ, Koh G, et al. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled study. Psychol Med 2004;34:983-990
43. Kavanagh DJ, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004;23:151-155
44. Drake RE, Wallach MA, Alverson HS, et al. Psychosocial aspects of substance abuse by clients with severe mental illness. J Nerv Ment Dis 2002;190:100-106
45. Laudet AB, Magura S, Vogel HS, et al. Support, mutual aid and recovery from dual diagnosis. Community Ment Health J 2000;36:457-476
46. Sigmon SC, Steingard S, Badger GJ, et al. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol 2000;8:509-517
47. Roll JM, Higgins ST, Steingard S, et al. Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study. Exp Gin Psychopharmacol 1998;6:157-161
48. Tidey JW, O'Neill SC, Higgins ST. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Exp Clin Psychopharmacol 2002;10:241-247
49. Roll JM, Chermack ST, Chudzynski JE. Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: a feasibility study. Psychiatry Res 2004;125:61-64
50. Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005;57:1128-1137
51. Campral [prescribing information]. St. Louis, Mo: Forest Pharmaceuticals, Inc; 2004. Available at: http:/www.campral.com/pdf/campral_pi.pdf. Accessed April 29, 2006
52. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003;12:242-252
53. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-1713
54. Jerrell JM, Ridgely MS. Evaluating changes in symptoms and functioning of dually diagnosed clients in specialized treatment. Psychiatr Serv 1995; 46:233-238
55. Xie H, McHugo GJ, Fox MB, et al. Substance abuse relapse in a 10-year prospective follow-up of clients with mental and substance use disorders. Psychiatr Serv 2005;56:1282-1287
56. Alverson H, Alverson M, Drake RE. An ethnographic study of the longitudinal course of substance abuse among people with severe mental illness. Community Ment Health J 2000;36:557-569
57. Rollins AL, O'Neill SJ, Davis KE, et al. Substance abuse relapse and factors associated with relapse in an inner-city sample of patients with dual diagnoses. Psychiatr Serv 2005;56:1274-1281
58. Davis KE, O'Neill SJ. A focus group analysis of relapse prevention strategies for persons with substance use and mental disorders. Psychiatr Serv 2005;56:1288-1291
59. Harris M, Fallot RD, Berley RW. Qualitative interviews on substance abuse relapse and prevention among female trauma survivors. Psychiatr Serv 2005;56:1292-1296